Policy Briefs
Filters
TOPICS
POPULATIONS
Categories
This policy brief provides lessons learned from the longer-standing experiences of delivering Long Acting Injectables (LAIs) for other chronic conditions in the fields of mental health and addiction offering insights into the use of newly available LAIs for HIV prevention and treatment.
This policy brief describes how re-entry has been associated with increased, illness, mortality, and risky health behaviors. The brief highlights the process of community re-entry presenting a crucial opportunity to link individuals with needed health and social services. This brief looks to HIV, a pandemic predating COVID-19, in order to draw broader lessons for addressing the needs of incarcerated populations in the United States during re-entry.
This policy brief describes the criminalization of commercial sex trade and regulatory frameworks seeking to regulate it differ across the globe. These efforts are described into four models of criminalization and regulation which include criminalize sex trade, criminalize clients (also known as the Nordic or End Demand model), regulate sex trade, and decriminalize sex trade.
This policy brief referred to as the White Paper – A Way Forward describes how Black men who have sex with men (BMSM), lag behind in PrEP use despite the fact that they are a population disproportionately affected by HIV/AIDS and represent one of the single largest groups of new cases in the US each year. The minimal use of PrEP by BMSM, coupled with healthcare provider anxieties about prescribing PrEP, may reduce the potential positive effect of PrEP in reducing HIV infection rates in this disproportionately impacted population.
This policy brief referred to as the White Paper describes how Black men who have sex with men (BMSM), lag behind in PrEP use despite the fact that they are a population disproportionately affected by HIV/AIDS and represent one of the single largest groups of new cases in the US each year.
The Use of HIV Over-the Counter (OTC) Test in California from April to September 2013 – Policy Brief
This policy brief examines the distribution, usage, and results of the HIV OTC test for a six-month period (April 1, 2013, through September 30, 2013) to determine how the HIV OTC test is being used thus far in California, an initial start-up period. This frame was selected as most manufacturing and distribution challenges had been overcome, and the HIV OTC test was generally available to consumers throughout California.
This policy brief examined how health insurance available through Covered California could cost more than some people living with HIV/AIDS can afford, undermining an important HIV prevention strategy: adherence to medication and engagement in care. People living with HIV/AIDS (PLWHA) who adhere to their drug regimens can reduce their viral load to undetectable levels, making them less likely to transmit HIV, and creating a public health imperative to reduce barriers to
care and treatment for PLWHA.
This policy brief examined how health insurance available through Covered California could cost more than some people living with HIV/AIDS can afford, undermining an important HIV prevention strategy: adherence to medication and engagement in care. People living with HIV/AIDS (PLWHA) who adhere to their drug regimens can reduce their viral load to undetectable levels, making them less likely to transmit HIV, and creating a public health imperative to reduce barriers to care and treatment for PLWHA.
This policy brief examines the recently proposed AB999, which would require the California Department of Corrections and Rehabilitation (CDCR) to develop a five-year plan to make condoms available in all California prisons. AB999 would instruct CDCR to use funds from the budget to provide condoms and condom dispensing machines at all California prisons by December 2019.
This policy brief describes the disproportionate prevalence of HIV among individuals in the correctional system. This policy brief elucidates the problem and recommends policies that prisons and jails in California could undertake to reduce new infections and treat existing ones.
This policy brief discusses how ADAP only covers a limited range of drugs – some 184 name brand and generic drugs necessary to successfully treat HIV/AIDS and related conditions. ADAP’s low-income beneficiaries must pay for drugs not on the ADAP formulary, and for other health care costs associated with HIV disease. Under the governor’s cost-sharing proposals, these clients would face significant increases in the amount of out-of pocket costs they will be expected to meet just to access medications they must have to maintain their health.
This factsheet , entitled HIV Among Gay and Bisexual Men explains how as a group, gay, bisexual, and other MSM have an increased chance of being exposed to HIV because of the large number of MSM living with HIV. Results of HIV testing conducted in 21 cities indicated that 19% of MSM tested in 2008 were HIV-positive and that HIV prevalence increased with increasing age and decreased with increasing education and income. Men aged 40 years and older were more likely than men aged 18–39 to have HIV.
This policy brief discusses the cost benefits for California to expand HIV surveillance efforts to add persons already in care to the HIV names based registry. It is estimated that each additional case registered would add $1675-$1707 to Ryan White allocations, but cost of only $992 to register. An additional $4.7 million would flow to the state as a result of adding 2800 cases to the registry.
This policy briefs addresses how will new cost-sharing fees proposed for the AIDS Drug Assistance Program affect people living with HIV and AIDS (PLWHA) in California. The governor’s cost-sharing proposal for ADAP will likely be a significant financial barrier to ADAP’s low-income beneficiaries. This is particularly problematic considering the high costs of these life-saving medications.
The governor’s cost-sharing proposal for ADAP will likely be a significant financial barrier to ADAP’s low-income beneficiaries. This is particularly problematic considering the high costs of these life-saving medications. Most ADAP beneficiaries could not afford their medications if they were financially unable to access the ADAP program.